212061-29-5

Basic information

• Product Name: 5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine
• Synonyms: 5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine
• CAS NO: 212061-29-5
• Molecular Weight: 647.725
• Mol File: 212061-29-5.mol
• Article Data: 87

Chemical Properties

• CAS DataBase Reference: 5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine(212061-29-5)
• EPA Substance Registry System: 5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine(212061-29-5)

Safety Data

• Hazardous Substances Data: 212061-29-5(Hazardous Substances Data)

Upstream product

• 26879-47-0 1-(β-L-ribofuranosyl)thymine 
• 854751-16-9 chloro-bis-(2-methoxy-phenyl)-phenyl-methane 
• 212061-28-4 2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methyluridine 
• 212061-25-1 5'-O-(tert-butyldiphenylsilyl)-2'-O-[2-[(2,3-dihydro-1,3-dioxo-1H-isoindol-2-yl)oxy]ethyl]-5-methyluridine 
• 212061-26-2 2'-O-[(2-formadoxyiminooxy)ethyl]-5'-O-tert-butyldiphenylsilyl-5-methyluridine 
• 212061-27-3 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N dimethylaminooxyethyl]-5-methyluridine 
• 258501-33-6 1-{5-(tert-butyl-diphenyl-silanyloxymethyl)-4-hydroxy-3-[2-(N-methyl-aminooxy)-ethoxy]-tetrahydro-furan-2-yl}-5-methyl-1H-pyrimidine-2,4-dione 
• 212061-24-0 5'-O-(tert-butyldiphenylsilyl)-2'-O-(2-hydroxyethyl)-5-methyluridine 
• 171763-19-2 5'-O-tert-butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine 
• 22423-26-3 O-2,2'-cyclo-5-methyluridine 
• 40615-36-9 4,4'-dimethoxytrityl chloride 

Relevant articles and documents

METHODS FOR THE PREVENTION AND TREATMENT OF MAJOR ADVERSE CARDIOVASCULAR EVENTS USING COMPOUNDS THAT MODULATE APOLIPOPROTEIN B

Provided herein, for example, are methods generally relating to preventing, treating and/or managing a major adverse cardiovascular event in a subject with a disease or condition at risk for a major adverse cardiovascular event, e.g., familial hypercholesterolemia. Also provided herein are methods relating to administering to the patient a therapeutically effective amount of an antisense oligonucleotide having a nucleobase SEQ ID NO: 247 (e.g., mipomersen).

Antisense modulation of CD40 ligand expression

Antisense compounds, compositions and methods are provided for modulating the expression of CD40 ligand. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40 ligand. Methods of using these compounds for modulation of CD40 ligand expression and for treatment of diseases associated with expression of CD40 ligand are provided.

ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION

Antisense compounds, compositions and methods are provided for modulating the expression of stearoyl-CoA desaturase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding stearoyl-CoA desaturase. Methods of using these compounds for modulation of stearoyl-CoA desaturase expression and for treatment of diseases associated with expression of stearoyl-CoA desaturase are provided.